Finasteride and Topical Minoxidil to Dutasteride and Oral Minoxidil. Is RU58841 still helping? Progress Pictures 10/1/2025
The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil, questioning the effectiveness and safety of continuing RU58841. They experienced hair loss improvement initially but are now considering stopping RU58841 due to cost and safety concerns.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Adding Topical Dutasteride on top of Oral Finasteride & Oral Minoxidil (19m)
The user experienced gradual hair thinning since 2021 and tried various treatments including topical minoxidil, rosemary oil, oral finasteride, oral minoxidil, RU58841, and oral dutasteride. They are considering switching to daily finasteride and adding topical dutasteride, tretinoin, and microneedling due to side effects from oral dutasteride.
community Hair loss still progressing despite finasteride, dutasteride, oral minoxidil, and trying RU58841. What next?
Despite using finasteride, dutasteride, oral minoxidil, and RU58841, hair loss continues to progress. Options considered include increasing dutasteride or minoxidil doses, adding topical treatments, and exploring other potential causes of hair loss.
community 5 year progress on fin/dut and topical/oral minoxidil
The user shared their 5-year hair regrowth journey using oral finasteride, oral dutasteride, topical and oral minoxidil, and a hair transplant. They experienced significant hair improvement without major side effects, although RU58841 was not effective for them.
community 24M – Started Finasteride at 21, Initially Regrew a Good Amount of Hair but Then Plateaued; Now on Daily Dutasteride + Topical Minoxidil/Finasteride – Diffuse Thinning and No Major Regrowth, Looking for Other Options
A 24-year-old male has been using finasteride and topical minoxidil since age 21, with initial hair regrowth that plateaued, and is now on daily dutasteride and topical treatments but still experiencing diffuse thinning. Suggestions include switching to oral minoxidil, increasing dutasteride dosage, trying topical RU58841, adding microneedling, and considering keto shampoo and red light therapy.
community September - december with fin + oral & topical min + ru58841.
The user experienced hair regrowth using finasteride, oral and topical minoxidil, and RU58841, despite initial shedding. They also transitioned from finasteride to dutasteride and addressed scalp issues with a folliculitis shampoo.
Related Research
6 / 6 results
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Системная терапия больных андрогенетической алопецией
Some treatments like minoxidil, finasteride, and dutasteride are effective for hair loss, but there's no agreed best treatment.
research Тіе Modern treatment of androgenetic alopecia
This review examines the molecular mechanisms and current treatment options for androgenetic alopecia, highlighting potential future therapies but providing no new experimental findings.
research Therapeutic strategies for treating hair loss
This article discusses the need for rational strategies in developing hair loss drugs targeting specific events in hair follicle cycling, reporting no clinical findings but emphasizing the importance of understanding molecular controls.
research Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.